Prostate Cancer News and Research

RSS

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

Genomic Deletions Drive Development of Melanoma Drug Resistance

Melanoma is the deadliest form of skin cancer. With global incidence rates rising, new, more effective treatments are necessary to alleviate the health burden of the disease. Important advances in recent years include doctors using genetic tests to look for specific mutations they can target for more personalised, effective treatment.

15 Apr 2024

Understanding Prostate Cancer Disparities Through Proteogenomics

Certain proteogenomic signatures in the prostate cancers of men of African and European ancestries were associated with higher risk of metastasis and/or recurrence of the disease, according to a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2024, held April 5-10.

10 Apr 2024

Large Study Finds 187 New Genetic Variants Linked to Prostate Cancer

A globe-spanning scientific team has compiled the most comprehensive list of genetic variants associated with prostate cancer risk -; 451 in all -; through a whole-genome analysis that ranks as the largest and most diverse investigation into prostate cancer genetics yet.

10 Nov 2023

Novel Activation Mechanism for First Identified Oncogene

In the late 1970s, the link between the c-Src gene and cancer was unveiled, marking the identification of the inaugural oncogene.

1 Nov 2023

Targeted MicroRNA-34a Therapy Shows Promise in Slowing Tumor Growth in Mice

A new cancer therapy developed by Purdue University researchers attacks tumors by tricking cancer cells into absorbing a snippet of RNA that naturally blocks cell division.

5 Sep 2023

New Insights Into How Cells Maintain Optimal Health

A group of researchers has unearthed the secrets behind a tiny but crucial protein that shuttles zinc ions (Zn2+) within our bodies. The discovery offers a deeper understanding of how our cells maintain optimal health.

4 Sep 2023

New Findings May Provide Useful Therapeutic Approach for Treating Breast Cancer Patients

A new editorial paper was published in Oncotarget's Volume 14 on June 12, 2023, entitled, "Are cis-spliced fusion proteins pathological in more aggressive luminal breast cancer?"

21 Aug 2023

Study Offers New Insights Into Neuroendocrine Transdifferentiation in Breast and Prostate Cancer Biology

A new editorial paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 8, entitled, "The senescence-associated secretory phenotype induces neuroendocrine transdifferentiation."

15 May 2023

New CAR T Strategy Offers a Dual-Targeting Mechanism to Fight Bone Metastatic Prostate Cancer

Prostate cancer frequently metastasizes to the bone and is incurable. Moffitt Cancer Center researchers are working to identify new treatment options for this subset of patients.

4 May 2023

Mirror-Image Versions of a Small Molecule Pave New Way for Cancer Drug Discovery

Scripps Research scientists have developed a new strategy for identifying small molecules that can change the function of proteins, offering a promising path for discovering targeted drugs.

28 Apr 2023

High-Throughput Assay to Analyze the Effects of CAR-T Cells Using Image Cytometry

The April 2023 issue of SLAS Discovery contains six full-length articles and one mini-review covering high-throughput screening (HTS) for protease-inhibiting drugs, high-content phenotypic screening and other life sciences research.

28 Apr 2023

Scientists Illuminate the Mechanism that Raises and Lowers PSMA Expression in Prostate Cancer

Like the better-known prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA) is a biomarker that can tell physicians much about a patient's metastatic prostate cancer.

11 Apr 2023

Novel Genes Could Serve as Predictive Biomarkers for PARP Inhibitor Response in Prostate Cancer

Prostate cancer tumors harboring BRCA1/2 mutations are exceptionally sensitive to PARP inhibitors, while genomic alterations in other DNA damage response (DDR) genes are less responsive.

5 Apr 2023

New combination therapy regimen may reduce prostate cancer progression or death by 37%

TALAPRO-2, a study led by Neeraj Agarwal, MD, FASCO, demonstrated that using TALZENNA, in combination with XTANDI, may reduce the risk of disease progression or death by 37%.

20 Mar 2023

First molecular images of olfaction sets the stage to create novel smells

Breaking a longstanding impasse in our understanding of olfaction, scientists at UC San Francisco (UCSF) have created the first molecular-level, 3D picture of how an odor molecule activates a human odorant receptor, a crucial step in deciphering the sense of smell.

16 Mar 2023

Significance of large-scale genetic studies in men of African ancestry

Investigators at USC’s Keck School of Medicine directed the meta-analysis, which discovered nine new genetic variants that boost the risk of prostate cancer in an under researched population, including a genetic risk score connected to aggressive forms of the disease.

6 Mar 2023

Scientists develop new design principles to improve cancer vaccines

A new way to significantly increase the potency of almost any vaccine has been developed by researchers from the International Institute for Nanotechnology at Northwestern University.

1 Feb 2023

A 3D explanation of SPOP’s role in cancer

The protein SPOP, which also plays a role in endometrial, uterine, and other cancers, is the most mutated in prostate cancer. Despite its significance, it is still unclear how SPOP mutations cause cancer.

26 Jan 2023

Point-of-care program boosts genetic testing for prostate cancer

Certain prostate cancer patients have genetic mutations that could affect how they are treated. According to a study published in Urology Practice®, an Official Journal of the American Urological Association (AUA), a comprehensive, on-site genetic testing program developed by urologists could help close the gap for this underutilized resource.

16 Dec 2022

Preventing protein-protein interactions with a new tool

Proteins constantly interact with one another inside cells to perform various tasks. Blocking the binding of two or more proteins appears as a potential treatment for some diseases where these functions are altered.

1 Dec 2022